|
|
Post by orlon on Mar 25, 2017 16:18:13 GMT -5
Just why Afrezza is not selling after almost two years of FDA approval? Keep it simple please as my mind is already overloaded.
|
|
|
|
Post by peppy on Mar 25, 2017 16:31:12 GMT -5
physicians are not prescribing it Refill rates suspect.
physicians need to learn the titration.
insurance has not been covering it. 70% prescriptions can be filled with pre-authorization.
The old not willing to change now. Too worn down by the disease.
There is a learning curve no matter what rapid acting meal time insulin you are on.
Type twos: endo relunctant to start insulin on the insulin naïve.
now with the possible new afrezza ultra-rapid and the new ultra rapid plus basal dual patent, perhaps endo's will consider the metformin with combination injectable therapy for type two?
www.screencast.com/t/nOwBa4aaA
Killing you softly with it's song, rapid acting mealtime insulin
www.screencast.com/t/r2tVogLoR
follow the money.
*In need of a catchy slogan. Afrezza, Insulin you can take. peaks in 15 mins, baseline in 3 hours.
|
|
|
|
Post by mnkdfann on Mar 25, 2017 16:59:48 GMT -5
*In need of a catchy slogan. Afrezza, Insulin you can take. peaks in 15 mins, baseline in 3 hours.
No time for the old in and out? youtu.be/NUNOJtfYKcQ "Meet the new 'In and Out': Afrezza!" |
|
|
|
Post by rockstarrick on Mar 25, 2017 19:04:36 GMT -5
|
|
|
|
Post by roguesuerte on Mar 25, 2017 22:46:39 GMT -5
Promotional efforts terrible under SNY and even worse almost nonexistent with relaunch, Bad Bad Bad. Catchy promotion would be to use Duckfiabetes logo with Duckfiabetes with Afrezza inhalable insulin. Sticking it to the pricks!(exlamtion point susbstituted with inhaler picture.
|
|
|
|
Post by slugworth008 on Mar 26, 2017 10:02:17 GMT -5
I'm right there with you Rock - Absolutely unacceptable to see this at this stage of the game. WTF are they thinking. My blood boiled when I read this. Are you f-ing kidding me. Mike - Matt...HELLO !!!!!! |
|
|
|
Post by peppy on Mar 26, 2017 10:29:17 GMT -5
I'm right there with you Rock - Absolutely unacceptable to see this at this stage of the game. WTF are they thinking. My blood boiled when I read this. Are you f-ing kidding me. Mike - Matt...HELLO !!!!!! insurance is not covering at those prices. hard to understand those prices. I thought the prices were/would be running $373 a titration pack. These are retail prices? no insurance? $614.00? This is for the smaller total unit concentration titration pack. the 4,8,12 unavailable. I have looked all over the afrezza professional site, no link or discussion of the titration pack.
Looks pretty damning.
|
|
|
|
Post by rombic33 on Mar 26, 2017 10:41:03 GMT -5
Don't want to think that someone paid someone some bribe to ruin something. But besides all good future and bad past only one thing is in my mind: Why constant 100 scripts per week for weeks, Why? It SHOULD BE GOING UP AND DOWN. The answer: only a handful of docs prescribing Afrezza. As per patients, better die but not to pay for some new treatment couple hundred a month cos no insurance coverage? Really? Are those people so poor? Don't buy a coffee twice a day and it will pay off your Afrezza easily. But M and M know the answer, IMO. Nasty thoughts, I know.
|
|
|
|
Post by mnkdfann on Mar 26, 2017 11:37:22 GMT -5
Don't want to think that someone paid someone some bribe to ruin something. But besides all good future and bad past only one thing is in my mind: Why constant 100 scripts per week for weeks, Why? It SHOULD BE GOING UP AND DOWN. The answer: only a handful of docs prescribing Afrezza. As per patients, better die but not to pay for some new treatment couple hundred a month cos no insurance coverage? Really? Are those people so poor? Don't buy a coffee twice a day and it will pay off your Afrezza easily. But M and M know the answer, IMO. Nasty thoughts, I know. Don't forget, from the last conference call, Castagna told us that one of the big prescribers died. "[O]ur big prescribers that really loved Afrezza did not come back on Board. And in fact, one of them passed away unfortunately, and that did hurt the Q4 performance." seekingalpha.com/article/4056011-mannkinds-mnkd-ceo-matthew-pfeffer-q4-2016-results-earnings-call-transcriptI mean, thank God only one of the prescribers passed away! But what about the other prescribers; how healthy are they? And what if one of the few remaining prescribers hurts his or her prescription writing hand? I hope Mannkind has taken out 'key man' insurance on all of these people. |
|
|
|
Post by peppy on Mar 26, 2017 11:57:05 GMT -5
it looks to me there is a definite distribution problem. and I know nothing about distribution. "you going to pay, you going to play? hmmm if the price of the 4/8 unit titration package is $614 at walmart, what does mnkd receive on the sale?
|
|
|
|
Post by agedhippie on Mar 26, 2017 12:36:37 GMT -5
it looks to me there is a definite distribution problem. and I know nothing about distribution. "you going to pay, you going to play? hmmm if the price of the 4/8 unit titration package is $614 at walmart, what does mnkd receive on the sale?
My guess is twice the amount they receive on a standard pack. The titration pack is twice the size of the standard pack (180 vs. 90 cartridges) so the price looks right to me. |
|
|
|
Post by agedhippie on Mar 26, 2017 12:44:24 GMT -5
Don't forget, from the last conference call, Castagna told us that one of the big prescribers died. "[O]ur big prescribers that really loved Afrezza did not come back on Board. And in fact, one of them passed away unfortunately, and that did hurt the Q4 performance." I have no idea why he said that, it was an unforced error. For somebody who is meant to be a marketer it is unbelievably stupid because it reinforces the idea that Afrezza as a fringe product so they probably shouldn't get involved. They need to believe that there is a huge groundswell and that it's time to start prescribing. |
|
|
|
Post by sayhey24 on Mar 26, 2017 13:16:23 GMT -5
"[O]ur big prescribers that really loved Afrezza did not come back on Board. And in fact, one of them passed away unfortunately, and that did hurt the Q4 performance."
Does anyone know who this was and what the good doctor passed away from?
I think the answer to the original question is Big Money and Big Pharma is doing everything they can to convince doctors not to prescribe and are doing their best to influence the marketplace. The last thing they want is everyone understanding the value of monomer insulin and how it would change diabetes treatment. The Big know it have have been trying to develop it since the AspB10 developments.
To combat Big Pharma would take a huge TV and media blitz which MNKD does not have the money to do. Someone who wants to develop the Cloud Service will step forward. The question is when; next week; next month; ADA 2017?
I heard early insulin intervention is a big topic this year at ADA 2017. Is that true?
|
|
|
|
Post by sportsrancho on Mar 26, 2017 14:44:22 GMT -5
"[O]ur big prescribers that really loved Afrezza did not come back on Board. And in fact, one of them passed away unfortunately, and that did hurt the Q4 performance."
That doesn't make any sense? If they really loved Afrezza why aren't they on board? And why didn't they know right away and correct it?
And what patient would drop the drugs they are on because their doctor died?
The new rep that handles that area will know who the doctor referred his patients to and make sure the new doc is up to speed. And I'm sure they are working like crazy getting the others back on board.
And while I'm at it... I have another question for anyone who wants to answer:-) Are we sure the patients are being told to use a follow up dose? And that people have to buy more Afrezza because of it? ( Fine with me if that's how to get the best results.)
Tom's kids don't do that very often. They are not afraid to take enough. And don't need extra. But they are also not trying to be perfect or compete with their numbers.
And are the T2's needing more also?
|
|
|
|
Post by mnkdfann on Mar 26, 2017 15:09:17 GMT -5
"That doesn't make any sense?"
The answer is in the transcript I linked to.
"When we expected a certain amount of prescribers to come on Board and we did our forecast, we went back to them and said, what’s going on? What happened? We know you like the drug, you had a good history of prescribing. And one of the number one things we heard consistently was, I just need to see a rep far more often and [Afrezza is] just not top of mind."
|
|
